Trial Profile
A Phase 1b/2a Multicenter, Open-label, Dose-escalation Study to Determine the Maximum Tolerated Dose, Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of CC-220 as Monotherapy and in Combination With Other Treatments in Subjects With Multiple Myeloma
Status:
Active, no longer recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 01 Mar 2024
Price :
$35
*
At a glance
- Drugs Iberdomide (Primary) ; Bortezomib; Bortezomib; Carfilzomib; Daratumumab; Daratumumab; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Sponsors Celgene Corporation
- 27 Feb 2024 Planned End Date changed from 15 Oct 2029 to 6 Feb 2028.
- 27 Feb 2024 Planned primary completion date changed from 15 Oct 2029 to 15 Mar 2024.
- 12 Dec 2023 Results presented at the 65th American Society of Hematology Annual Meeting and Exposition